gene_symbol
ERBB2
hgnc_id
HGNC:3430
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
DIRECT
cytotoxicity_mechanism
Trastuzumab binds HER2 on tumor cells and engages Fcγ receptors on NK cells/macrophages to mediate antibody-dependent cellular cytotoxicity (ADCC), killing HER2-expressing cells; it may also inhibit signaling and modestly activate complement.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Binds HER2 extracellular domain (subdomain IV); blocks HER2 dimerization/signaling and mediates ADCC
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06328738
disease_id_num_tar_ref
2925
drug_id_num_tar_ref
7815